Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

• J. F. Cueva ^[1] ; S. Antolín ^[2] ; L. Calvo ^[2] ; I. Fernández ^[5] ; M. Ramos ^[6] ; L. de Paz ^[3] ; J. G. Mata ^[7] ; R. López ^[1] ; M. Constenla ^[8] ; E. Pérez ^[7] ; A. González ^[6] ; M. L. Pellón ^[3] ; S. Varela ^[9] ; T. López ^[4]
  1. [1] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  2. [2] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  3. [3] Complexo Hospitalario Universitario de Ferrol

     Complexo Hospitalario Universitario de Ferrol

     Ferrol, España

     
  4. [4] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  5. [5] Complejo Hospitalario Universitario Vigo, España
  6. [6] Centro Oncológico Galicia, España
  7. [7] Complejo Hospitalario Universitario Ourense, España
  8. [8] Complejo Hospitalario Universitario Pontevedra, España
  9. [9] Complejo Hospitalario Universitario Lugo, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 9 (September 2017), 2017, págs. 1067-1078
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • This Galician consensus statement is a joint oncologists/cardiologists initiative indented to establish basic recommendations on how to prevent and to manage the cardiotoxicity in breast cancer with the aim of ensuring an optimal cardiovascular care of these patients. A clinical screening of the patients before treatment is recommended to stratify them into a determined risk group based on their intrinsic cardiovascular risk factors and those extrinsic arose from breast cancer therapy, thereby providing individualized preventive and monitoring measures. Suitable initial and ongoing assessments for patients with low and moderate/high risk and planned treatment with anthracyclines and trastuzumab are given; also, measures aimed at preventing and correcting any modifiable risk factor are pointed out.